Inhalation of activated protein C: A possible new adjunctive intervention in acute respiratory distress syndrome.
Acute respiratory distress syndrome (ARDS) is a potential lethal disease. At present time no evidence based intervention reduces mortality. The pathophysiology of ARDS include intraalveolar fibrin deposition, hyperinflammation and reduced cellular host defense in the airspace. The normal lung activates protein C (PC) to activated protein C (APC), in contrast to the ARDS lung where the PC-APC axis is disrupted. The lungs have targets for inhaled APC as illustrated by a patient case with ARDS, unresponsive to conventional therapy. After inhalation of 190 mug/kg of APC (Drotrecogin alpha activated) three times a day for seven days, a clear reduction in infiltrates on chest X-ray and a 138% increase in oxygenation capacity as reflected by the PaO(2)/FiO(2) ratio was brought about. The patient, however, died later after cardiac arrest after suspected recurrence of the T-cell lymphoma. No local or systemic adverse effects was found related to the iAPC, during, after or at the time of death. It is suggested based on existing studies and the presented case that inhaled APC is a new treatment option in patients with ARDS - a hypothesis which should be substantiated in a larger series of ARDS patients.
Heslet
Lars
L
Department of Intensive Care ITA 4131;
Andersen
Jakob Steen
JS
Sengeløv
Henrik
H
Dahlbäck
Björn
B
Dalsgaard-Nielsen
Jorgen
J
Blood. 2004 Dec 15;104(13):3878-85
15339848
Am J Physiol Lung Cell Mol Physiol. 2006 Oct;291(4):L772-80
16751220
N Engl J Med. 2001 Mar 8;344(10):699-709
11236773
Crit Care Med. 2007 May;35(5):1362-8
17414732
Semin Thromb Hemost. 2006 Apr;32 Suppl 1:49-60
16673266
Thorax. 2007 Jul;62(7):608-16
17356058
Am J Physiol Lung Cell Mol Physiol. 2003 Sep;285(3):L514-21
12754194
J Immunol. 2006 Aug 15;177(4):2115-22
16887970
Crit Care Med. 2007 Jan;35(1):57-63
17080003
Chest. 1999 Oct;116(4):1012-8
10531167
Lancet. 2007 May 5;369(9572):1553-1564
17482987
Br J Pharmacol. 2006 Nov;149(6):740-6
17016502
Pediatr Res. 2005 Jul;58(1):10-4
15774850
Crit Care. 2003 Feb;7(1):23-38
12617738
Am J Respir Crit Care Med. 2003 Jun 15;167(12):1687-94
12615624
J Thromb Haemost. 2007 Jul;5 Suppl 1:73-80
17635713
Pediatr Pulmonol. 2007 Apr;42(4):380-5
17358043
Crit Care Med. 2001 Nov;29(11):2051-9
11700394
Am J Physiol Lung Cell Mol Physiol. 2006 Dec;291(6):L1246-55
16891399
N Engl J Med. 2006 Apr 20;354(16):1739-42
16625013
Crit Care Med. 2003 Apr;31(4 Suppl):S195-9
12682440
Blood. 2007 Apr 15;109(8):3161-72
17110453
Am J Respir Crit Care Med. 2005 May 15;171(10):1125-8
15750041
Curr Drug Targets. 2007 Apr;8(4):493-500
17430119
Eur Respir J. 1999 May;13(5):1029-36
10414400
Blood. 2003 Aug 15;102(4):1499-505
12714492
Chest. 1985 Feb;87(2):237-46
2981658
Chest. 2007 Mar;131(3):921-929
17356115
N Engl J Med. 2006 Apr 20;354(16):1671-84
16625008
Crit Care Med. 2006 Mar;34(3):871-7
16521285
J Immunol. 2006 Jan 15;176(2):1019-25
16393989
Am J Respir Cell Mol Biol. 2007 Apr;36(4):497-503
17099142
J Clin Oncol. 2006 Feb 1;24(4):643-9
16380411
Transplantation. 1995 Dec 27;60(12):1525-32
8545885
Semin Respir Crit Care Med. 2005 Oct;26(5):482-9
16267699
Blood. 2004 Mar 15;103(6):2196-204
14604971
Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1311-20
15860736
Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):454-62
10673185